Education
About Us
Working with TipRanks
Follow Us
IDEAYA Biosciences (IDYA)
NASDAQ:IDYA
IDYA Stock Chart & Stats
$31.95
$0.01(0.06%)
At close: 4:00 PM EST
$31.95
$0.01(0.06%)
Day’s Range― - ―
52-Week Range$13.45 - $33.64
Previous CloseN/A
Volume96.34K
Average Volume (3M)1.21M
Market Cap
$2.80B
Enterprise Value$1.68B
Total Cash (Recent Filing)$786.89M
Total Debt (Recent Filing)$27.25M
Price to Earnings (P/E)―
Beta1.57
Next Earnings
Mar 31, 2026EPS Estimate
-0.94Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.47
Shares Outstanding87,666,405
10 Day Avg. Volume927,154
30 Day Avg. Volume1,205,170
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)1.98
Price to Sales (P/S)299.87
P/FCF Ratio-8.35
Enterprise Value/Market Cap0.60
Enterprise Value/Revenue7.82
Enterprise Value/Gross Profit7.97
Enterprise Value/Ebitda-10.73
Forecast
1Y Price Target
$48.53Price Target Upside51.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessNeoadjuvant data from a trial showed impressive results, including tumor shrinkage in 83% of evaluable patients and significant eye preservation rates.
Financial StabilityWith cash reserves of $1.14 billion and a financial runway into 2030, there is an opportunity for long-term growth as the company executes on its lead programs.
Pipeline DevelopmentIND clearance and submissions for multiple projects indicate strong pipeline development efforts.
Bears Say
Competitive PressureSome headline figures for competitor ZL-1310 look numerically better than those reported by IDE849.
Market ConcernsSome investors want to see evidence of vision preservation through long-term outcomes data rather than simulated reductions.
Risk FactorsRisks to the rating and price target include potential clinical setbacks for darovasertib and longer-than-anticipated path to market.
IDEAYA Biosciences News
IDYA FAQ
What was IDEAYA Biosciences’s price range in the past 12 months?
IDEAYA Biosciences lowest stock price was $13.45 and its highest was $33.64 in the past 12 months.
What is IDEAYA Biosciences’s market cap?
IDEAYA Biosciences’s market cap is $2.80B.
When is IDEAYA Biosciences’s upcoming earnings report date?
IDEAYA Biosciences’s upcoming earnings report date is Mar 31, 2026 which is in 138 days.
How were IDEAYA Biosciences’s earnings last quarter?
IDEAYA Biosciences released its earnings results on Nov 04, 2025. The company reported $1.466 earnings per share for the quarter, beating the consensus estimate of -$0.827 by $2.293.
Is IDEAYA Biosciences overvalued?
According to Wall Street analysts IDEAYA Biosciences’s price is currently Undervalued.
Does IDEAYA Biosciences pay dividends?
IDEAYA Biosciences does not currently pay dividends.
What is IDEAYA Biosciences’s EPS estimate?
IDEAYA Biosciences’s EPS estimate is -0.94.
How many shares outstanding does IDEAYA Biosciences have?
IDEAYA Biosciences has 87,666,405 shares outstanding.
What happened to IDEAYA Biosciences’s price movement after its last earnings report?
IDEAYA Biosciences reported an EPS of $1.466 in its last earnings report, beating expectations of -$0.827. Following the earnings report the stock price went down -2.806%.
Which hedge fund is a major shareholder of IDEAYA Biosciences?
Currently, no hedge funds are holding shares in IDYA
IDEAYA Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$48.53 (51.89% Upside)
$48.53 (51.89% Upside)
Blogger Sentiment
Bullish
IDYA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 239.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days <0.1%
Last 30 Days ▲ 8.4%
Last 30 Days ▲ 8.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.13%
12-Months-Change
Fundamentals
Return on Equity
-14.15%
Trailing 12-Months
Asset Growth
-4.41%
Trailing 12-Months
Company Description
IDEAYA Biosciences
IDEAYA Biosciences (IDYA) is a biotechnology company focused on the discovery and development of targeted therapeutics for cancer and other genetic diseases. The company specializes in precision medicine, leveraging its proprietary drug discovery platforms to identify and develop small molecule therapeutics that target specific genetic mutations and pathways. IDEAYA operates primarily in the oncology sector and is committed to advancing innovative treatment options for patients with unmet medical needs.
IDYA Stock 12 Month Forecast
Average Price Target
$48.53
▲(51.89% Upside)
Technical Analysis
Agios Pharma
―
Travere Therapeutics
―
Celcuity
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Ownership Overview
0.82% Insiders
35.37% Mutual Funds
0.01% Other Institutional Investors
51.30% Public Companies and
Individual Investors